Skip to main content
Lepu Biopharma Co., Ltd. logo

Lepu Biopharma Co., Ltd. — Investor Relations & Filings

Ticker · 2157 ISIN · CNE100004SM4 HKEX Manufacturing
Open in API
Filings indexed 240 across all filing types
Latest filing 2023-11-14 Proxy Solicitation & In…
Country HK Hong Kong
Listing HKEX 2157

About Lepu Biopharma Co., Ltd.

http://www.lepubiopharma.com

Lepu Biopharma Co., Ltd. is an innovation-driven biopharmaceutical company dedicated exclusively to the research and development of oncology therapeutics. The company focuses on advanced tumor treatment modalities, including targeted therapy and cancer immunotherapy. Its strategically built product pipeline encompasses a range of candidate drugs, notably Antibody-Drug Conjugates (ADCs), immunotherapies, and oncolytic virus drugs, with assets spanning clinical and preclinical development stages. Lepu Biopharma leverages its proprietary ADC technology platform to drive the development of innovative treatments. The company pursues domestic commercialization through dedicated sales infrastructure while actively seeking global market access, particularly in the US and European markets, via strategic partnerships and out-licensing agreements for its drug candidates.

Recent filings

Filing Released Lang Actions
PROXY FORM FOR USE AT THE 2023 SECOND EXTRAORDINARY GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a proxy form for use at the 2023 Second Extraordinary General Meeting (EGM) of Lepu Biopharma Co., Ltd. It contains detailed instructions for shareholders to appoint proxies and vote on specific resolutions related to the company's proposed quotation on the NEEQ, amendments to articles, and governance policies. The content is procedural and related to shareholder voting rather than a report or announcement of financial results or management commentary. It is not a full report like an Annual Report or Interim Report, nor is it a voting results announcement. It is a solicitation document for shareholder votes at a general meeting, which fits the definition of Proxy Solicitation & Information Statement (PSI). The document length and detail also support this classification rather than a brief announcement or regulatory filing.
2023-11-14 English
RESOLUTIONS RELATING TO THE PROPOSED ADDITIONAL METHOD FOR THE PUBLIC TRADING ON THE PRC DOMESTIC CAPITAL MARKET AND PROPOSED AMENDMENTS TO THE ARTICLES ANCILLARY TO THE PROPOSED QUOTATION
Regulatory Filings Classification · 95% confidence The document is an announcement from Lepu Biopharma Co., Ltd. regarding resolutions related to a proposed additional method for public trading on the PRC domestic capital market, specifically the National Equities Exchange and Quotations (NEEQ). It details proposed shareholder resolutions to be voted on at an Extraordinary General Meeting (EGM), including approval of the quotation of existing domestic shares on the NEEQ, amendments to the articles of association, and related governance policies. The document is an announcement of proposed resolutions and upcoming shareholder meeting materials rather than the actual meeting materials or minutes themselves. It does not contain financial statements or detailed financial data, nor is it a transcript or a report. It is a regulatory announcement informing shareholders and the market about the proposed resolutions and the upcoming EGM. Therefore, it fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2023-11-14 English
(1) RESOLUTIONS RELATING TO THE PROPOSED ADDITIONAL METHOD FOR THE PUBLIC TRADING ON THE PRC DOMESTIC CAPITAL MARKET&#x3b; (2) PROPOSED AMENDMENTS TO THE ARTICLES ANCILLARY TO THE PROPOSED QUOTATION&#
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a circular from Lepu Biopharma Co., Ltd. regarding resolutions for a proposed additional method for public trading on the PRC domestic capital market, proposed amendments to the articles of association, and notice of the 2023 second extraordinary general meeting (EGM). It includes detailed information about the EGM, the proposed resolutions, and proxy instructions. The document is lengthy (15,000 characters) and contains detailed content intended to inform shareholders to make decisions at the EGM. This type of document is typically classified as Proxy Solicitation & Information Statement (PSI), as it provides information and requests votes for the meeting. It is not a simple announcement or notice, nor is it a full annual or interim report, nor a voting result declaration. Therefore, the appropriate classification is PSI with high confidence.
2023-11-14 English
CONTINUING CONNECTED TRANSACTION CDMO SERVICES FRAMEWORK AGREEMENT
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a continuing connected transaction under a CDMO Services Framework Agreement between Lepu Biopharma Co., Ltd. and Lepu Medical. It discusses the terms of the agreement, the need for Independent Shareholders' approval, the establishment of an Independent Board Committee, and the upcoming Extraordinary General Meeting (EGM) to approve the transaction. The document is a regulatory announcement about a transaction requiring shareholder approval and does not contain financial statements or detailed financial results. It is not a full report like an Annual Report or Interim Report, nor is it a call transcript or earnings release. It is also not a proxy solicitation or voting results announcement but rather an announcement of a continuing connected transaction and related corporate governance matters. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-11-13 English
CLOSURE OF REGISTER OF MEMBERS FOR THE 2023 SECOND EXTRAORDINARY GENERAL MEETING TO BE HELD ON NOVEMBER 29, 2023
Regulatory Filings Classification · 95% confidence The document is an announcement from Lepu Biopharma Co., Ltd. regarding the closure of the register of members for the 2023 second extraordinary general meeting (EGM) to be held on November 29, 2023. It details the dates for the register closure and instructions for shareholders to be eligible to attend and vote at the EGM. It also mentions that the circular with details of the resolutions and proxy form will be sent later. The document is short (2582 characters) and serves as a notice about shareholder registration and meeting logistics rather than the meeting materials or voting results themselves. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into more specific categories like Declaration of Voting Results or Proxy Solicitation. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-11-09 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023
Regulatory Filings Classification · 95% confidence The document is a monthly return detailing movements in securities, specifically focusing on authorized/registered share capital and issued shares for Lepu Biopharma Co., Ltd. It includes confirmations related to securities issued during the month and compliance with listing rules. The document is structured as a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting share capital and share issuance movements for the month ended 31 October 2023. It does not contain financial statements, earnings data, or management discussion, nor is it a report or presentation. It is a regulatory filing reporting share capital and share movements, fitting the category of Regulatory Filings (RNS).
2023-11-03 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.